Transcutaneous electrical nerve stimulation is a low-cost, drug-free device sending mild pulses through skin pads to quiet pain. Its clearest benefit is pain relief during use, at a strong but comfortable setting. Beyond pain, support is firmest for easing leg stiffness and walking after stroke. Whether relief lasts between sessions remains uncertain. Risks are mostly mild skin irritation, except with pacemakers, implanted defibrillators, epilepsy, or neck or chest placement. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Pain intensity, 0–10 numeric rating scale | Reduction of 30% or more from own baseline | Defines response |
| Movement-evoked pain (0–10 during five sit-to-stand repetitions) | No established target; track change from own baseline | Captures activity-related relief |
| Skin at electrode sites | No established target; track redness, blistering or itching versus prior session | Safety check |
| Implanted cardiac device function | No established target; confirm no interference during supervised test stimulation | Determines whether use is possible |
| Resting heart rate (ear stimulation) | 60–100 beats per minute | Safety check; excessive slowing stops use |
| Heart rate variability, RMSSD (ear stimulation) | No established target; track change from own baseline | Marker of vagal activity |
| Bladder diary: incontinence, urgency and night-time voids per day (tibial stimulation) | No established target; track change from own baseline | Defines bladder response |
| Depression score, PHQ-9 (ear stimulation for low mood) | No established target; track change from own baseline | Tracks mood benefit |
Cadence: Pain ratings during and 30 minutes after each of the first sessions; structured review at 2 weeks, 4 weeks and 3 months, then every 6 months; skin checked at every session; for ear stimulation, pulse before and after the first week of sessions, then monthly; bladder diaries and mood questionnaires at 6 and 12 weeks. Lack of meaningful change by 4 weeks suggests non-response.